Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02835222 · ClinicalTrials.gov registry record · Phase 2

Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients

A Phase 2 study of Untreated Adult Acute Myeloid Leukemia, sponsored by Wake Forest University Health Sciences.

Active
Registry status
Phase 2
Development phase
57
Enrollment target
2
Study locations

NCT02835222 is a Phase 2 study of Untreated Adult Acute Myeloid Leukemia that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 57 participants, below the 104-participant average among 12 other Untreated Adult Acute Myeloid Leukemia trials with a reported enrollment target (45% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02835222, a Phase 2 study of Untreated Adult Acute Myeloid Leukemia, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
57 participants
Enrollment target
2
Study locations

Study Summary

This pilot phase II trial studies how well selinexor works when given together with induction, consolidation, and maintenance therapy in treating older patients with acute myeloid leukemia. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine and daunorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selinexor with induction, consolidation, and maintenance therapy may kill more cancer cells in older patients with acute myeloid leukemia.

Conditions Studied

Untreated Adult Acute Myeloid Leukemia

Interventions

  • DRUG Selinexor
  • DRUG Cytarabine
  • DRUG Daunorubicin Hydrochloride

Study Locations (2)

North Carolina

  • Comprehensive Cancer Center of Wake Forest University - Winston-Salem

Virginia

  • Virginia Commonwealth University Massey Cancer Center - Richmond

Trial Details

FieldValue
Enrollment Target 57 participants
Start Date 2018-02-02
Est. Completion 2027-02-26
Phase Phase 2

Sponsor

Wake Forest University Health Sciences

1,140 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02835222

The ClinicalTrials.gov registry entry for NCT02835222 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 104-participant average among 12 other Untreated Adult Acute Myeloid Leukemia trials with a reported enrollment target (45% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Untreated Adult Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Selinexor is the first listed.

NCT02835222 reports 2 study locations spanning 2 distinct geographic areas - top geographies include North Carolina, Virginia.

Frequently Asked Questions

What is clinical trial NCT02835222 about?

NCT02835222 is a clinical study titled "Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients". This pilot phase II trial studies how well selinexor works when given together with induction, consolidation, and maintenance therapy in treating older patients with acute myeloid leukemia. Selinexor may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs use...

What is the current status of trial NCT02835222?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 57 participants. The study started on 2018-02-02. Estimated completion is 2027-02-26.

What conditions does trial NCT02835222 study?

This clinical trial studies the following conditions: Untreated Adult Acute Myeloid Leukemia.

What interventions are being tested in trial NCT02835222?

The interventions under investigation include: Selinexor (DRUG), Cytarabine (DRUG), Daunorubicin Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT02835222?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02835222 being conducted?

This trial has 2 study locations across North Carolina, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Untreated Adult Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Untreated Adult Acute Myeloid Leukemia

All registered trials for this condition

North Carolina

All trials with a study site in North Carolina

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.